MARKET

ORKA

ORKA

Oruka Therapeutics Inc
NASDAQ
90.60
+3.97
+4.58%
After Hours: 90.58 -0.02 -0.02% 19:34 06/26 EDT
OPEN
85.54
PREV CLOSE
86.63
HIGH
91.12
LOW
85.20
VOLUME
4.73M
TURNOVER
--
52 WEEK HIGH
91.12
52 WEEK LOW
10.77
MARKET CAP
5.46B
P/E (TTM)
-37.9159
1D
5D
1M
3M
1Y
5Y
1D
Oruka Therapeutics Price Target Maintained With a $120.00/Share by HC Wainwright & Co.
Dow Jones · 5d ago
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target
Benzinga · 5d ago
Analysts’ Top Healthcare Picks: PROCEPT BioRobotics (PRCT), Prime Medicine, Inc. (PRME)
TipRanks · 5d ago
Oruka Therapeutics SVP Finance Arjun Agarwal disposes of 1,587 common shares worth $127,454.28
PUBT · 5d ago
Monday's ETF Movers: XBI, RONB
NASDAQ · 6d ago
Apogee Therapeutics, Definium Therapeutics, Baldwin Insurance And Other Big Stocks Moving Higher On Monday
Benzinga · 6d ago
Monday Sector Leaders: Biotechnology, Shipping Stocks
NASDAQ · 6d ago
BTIG says others may be interested in Apogee Therapeutics
TipRanks · 6d ago
More
About ORKA
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).

Webull offers Oruka Therapeutics Inc stock information, including NASDAQ: ORKA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORKA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ORKA stock methods without spending real money on the virtual paper trading platform.